Brief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
07/08/2026 02:23
BRIEF-Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma Aug 7 (Reuters) - CARsgen Therapeutics Holdings Ltd 2171.HK:
CT1190B RECEIVES IND CLEARANCE FROM NMPA FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Further company coverage: 2171.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer